PALO
ALTO, Calif., Sept. 5,
2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.
(Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused
on the development of innovative therapies for rare metabolic
diseases, today announced that David
Apelian, MD, PhD, MBA, CEO of Eiger, will present a company
overview at the H.C. Wainwright 25th Annual Global
Investment Conference on Monday, September
11, 2023 at 7:00 AM ET in
New York, NY. Eiger will also host
one-on-one meetings with investors at the conference.
The presentation will be available on the Investors section of
the Eiger BioPharmaceuticals website at www.eigerbio.com. A replay
of the presentation will be available on the website for at least
90 days.
About Eiger
Eiger is a commercial-stage
biopharmaceutical company focused on the development of innovative
therapies for rare metabolic diseases. Eiger's lead product
candidate, avexitide, is a well characterized, first-in-class GLP-1
antagonist being developed for the treatment of post-bariatric
hypoglycemia (PBH) and congenital hyperinsulinism (HI). Avexitide
is the only drug in development for PBH with Breakthrough Therapy
designation from the FDA.
For additional information about Eiger and its clinical
programs, please visit www.eigerbio.com.
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Media:
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-present-at-hc-wainwright-25th-annual-global-investment-conference-301918284.html
SOURCE Eiger BioPharmaceuticals, Inc.